Reflecting on Our Impact and Looking to the Future

After an amazing five years of working with some of the most passionate leaders in women’s health, I have ended my time as Medicines360 CEO to embark on a new venture. As I look back on the past five years, I’m incredibility proud of the impact we’ve made at Medicines360 for women. Not a day has gone by during my time here that I didn’t love my job. We’ve accomplished so much together, and I am excited to continue my role as Board Observer of Medicines360. During my time as CEO, we expanded access to our products to help women get the medicines they need. We improve access by zeroing in on the most pressing needs in women’s health and creating new models to address them.

In the U.S., we’ve developed a high-quality, affordable, hormonal IUD. In the last five years, we have continued to file for and receive FDA supplemental approvals for extended durations of use for our product and we were the first hormonal IUD to be approved for 6 years of contraceptive use. This helped lower the cost of use per year, making a positive impact for underserved populations. We have also focused on improving equity in the marketplace by reaching women who would otherwise have trouble affording this type of birth control.

In several low- and middle-income countries, we launched the Avibela® Program through our subsidiary, Impact RH360, to make the hormonal IUD available. We’ve worked hand-in-hand with global NGOs to support registration, provider training, and product launch. To date, we’ve registered our product in four African countries with a goal to file for registration in 25 African countries by 2025. We are on track to provide more than 7,800 units of our IUD to four different African countries by the end of this year.

Our affordable, high quality products address unmet needs, and so does our educational work. Last year, we created a campaign to break down stigma-related barriers women face in accessing reproductive health care. #NotAwkward encourages positive and informative conversations about birth control and reproductive health. The idea is that anyone can make a difference for others just by sharing their story and that women can learn from and lean on each other.

As we look to the future, we know that gaps in women’s health expand far beyond birth control. The women’s health landscape is fraught with challenges. Systemic barriers lead to widespread disparities in outcomes for women. On top of that, stigma and a constant politicizing of women’s health leave women lacking answers and access. As one of the first global nonprofit pharmaceutical companies, we are uniquely poised to break down barriers women face accessing the medicines they need. Not only do we focus on products that fill gaps, we amplify women’s experiences to show them they are not alone and help them find the answers they need.

In 2021 and beyond, Medicines360 will continue working on health equity by addressing disparities and gaps within our healthcare system. Not only will the organization work to expand birth control access through our current products, we will assess other gaps and create new products to help women get the medicines they need at an affordable price.

As I begin my next journey, our Chief Operating Officer, Andrea Olariu, MD, PhD is poised to take Medicines360 into the new year stronger than ever, as we look to address more barriers within women’s health. As the Interim CEO, Dr. Olariu will lead Medicines360, maximizing our impact and improving the sustainability of our organization. As we expand focus, we will stay true to our mission to develop essential women’s health products that are facing drug shortages or have high prices impacting availability.

I am excited to see what Medicines360 will accomplish, as I know the sky is the limit for this organization. This team of experts, trailblazers, and builders will continue to shape new systems and construct solutions for the challenges women face as long as they persist.

Signing off and wishing you all the best,

Jessica Grossman, MD

About Medicines360

Located in San Francisco, California, Medicines360 is a global nonprofit pharmaceutical organization with a mission to accelerate the timeline from health innovation to access for all women. Medicines360 is committed to working with healthcare providers, advocacy groups, and patients to deliver innovative and meaningful treatments that help women around the world have greater access to the medicines they need. For more information, visit

Share This

AVIBELA can be made available in the following 88 countries

  1. Algeria
  2. Angola
  3. Bangladesh
  4. Belize
  5. Benin
  6. Bhutan
  7. Botswana
  8. Burkina Faso
  9. Burundi
  10. Cambodia
  11. Cameroon
  12. Cape Verde
  13. Central African Republic
  14. Chad
  15. Comoros
  16. Costa Rica
  17. Cuba
  18. Democratic Republic of the Congo
  19. Djibouti
  20. Dominica
  21. Dominican Republic
  22. Egypt
  23. El Salvador
  24. Equatorial Guinea
  25. Eritrea
  26. Ethiopia
  27. Gabon
  28. Ghana
  29. Grenada
  30. Guatemala
  31. Guinea
  32. Guinea-Bissau
  33. Haiti
  34. Honduras
  35. India
  36. Indonesia
  37. Ivory Coast
  38. Jamaica
  39. Kenya
  40. Lao PDR
  41. Lesotho
  42. Liberia
  43. Libya
  44. Madagascar
  45. Malawi
  46. Malaysia
  47. Maldives
  48. Mali
  49. Mauritania
  50. Mauritius
  51. Mayotte
  52. Morocco
  53. Mozambique
  54. Myanmar
  55. Namibia
  56. Nepal
  57. Nicaragua
  58. Niger
  59. Nigeria
  60. Pakistan
  61. Panama
  62. Papua New Guinea
  63. Philippines
  64. Republic of the Congo
  65. Rwanda
  66. Sao Tome and Principe
  67. Senegal
  68. Seychelles
  69. Sierra Leone
  70. Somalia
  71. South Africa
  72. South Sudan
  73. Sri Lanka
  74. Kitts and Nevis
  75. Lucia
  76. Vincent & the Grenadines
  77. Sudan
  78. Swaziland
  79. Tanzania
  80. Thailand
  81. The Gambia
  82. Timor-Leste
  83. Togo
  84. Tunisia
  85. Uganda
  86. Vietnam
  87. Zambia
  88. Sri Lanka

Tina Raine-Bennett, MD, MPH, FACOG

Chief Executive Officer

Tina Raine-Bennett, MD, MPH, is CEO of Medicines360. Previously, she served as a senior research scientist at the Kaiser Permanente Northern California Division of Research and the research director of the Women’s Health Research Institute. She is a Board-Certified Obstetrician Gynecologist who received her medical training at the University of California, San Diego, and post-graduate residency training and MPH at the University of Washington in Seattle, where she also completed a Robert Wood Johnson Clinical Scholars Fellowship. She was also senior staff physician at Kaiser Permanente and has a special interest in family planning and adolescent reproductive health.

As the director of the Women’s Health Research Institute, Dr. Raine-Bennett focused on expanding research on women’s health within the Division and translating women’s health research into clinical practice and policy within the Ob/Gyn departments in Northern California. She also promoted the involvement of clinicians in research designed to improve the health outcomes and healthcare experiences of women at Kaiser Permanente and women in general.

Prior to Kaiser Permanente, Dr. Raine-Bennett was a professor in the Department of Obstetrics, Gynecology, and Reproductive Sciences at University of California, San Francisco (UCSF). She was based at San Francisco General Hospital where she was also the medical director of the New Generation Health Center, a UCSF affiliate site that provides community-based reproductive health services. Dr. Raine-Bennett’s research has focused on contraceptive methods and on elucidating factors that influence contraceptive choice and continuation, and she was principal investigator on NIH grants to assess hormonal contraceptive use predictors and develop interventions to improve contraceptive access.

Her past and current research on emergency contraception has focused on the safety of making emergency contraception more accessible and she conducted a pivotal clinical trial to make emergency contraception available to teens without a prescription. She served on the editorial board of Obstetrics and Gynecology and has over 100 peer-reviewed publications. She was the Treasurer of the Board of Directors for the Society of Family Planning and Society of Family Planning Research Fund. She has also served as an examiner for the American Board of Obstetrics and Gynecology, and on national committees for the American College of Obstetrics and Gynecology and the National Medical Board of Planned Parenthood Federation of America.